Author Archives for Adeline Chauvigné

New partner | Majorelle Avocats

5 May 2024

Majorelle Avocats is a law firm specialising in labour law and social security law, based in Nantes and Paris. Its... View Article

OSE Immunotherapeutics announces H1 2021 results and provides a corporate update

5 May 2024

Positive final Phase 3 results for Tedopi® in non-small cell lung cancer (NSCLC) after ICI failure. Positive Phase 1 dose... View Article

Naobios manufactures FluGen Inc’s M2SR influenza vaccine candidate for upcoming clinical trials

5 May 2024

Naobios today announces the next phase in its partnership with FluGen, Inc., a clinical-stage vaccine company transforming vaccine efficacy in infectious... View Article

CLEAN CELLS INVESTS OVER €13M IN A NEW BIOPHARMACEUTICAL PRODUCTION SITE

5 May 2024

5,300 m2 new facility will quadruple analysis and production capacity, becoming largest site in Europe for biopharmaceuticals quality control services... View Article

Xenothera signs a memorandum of understanding with the Vietnamese conglomerate Vingroup

5 May 2024

Following discussions held under the authority of the Vietnamese Minister of Health, Trân Van Thuân, the Nantes-based company XENOTHERA, which... View Article

Valneva Completes Recruitment of Elderly Participants in Phase 3 Trial of its Inactivated COVID-19 Vaccine

5 May 2024

Valneva, a specialty vaccine company, today announced that it has completed recruitment of the initial cohort of elderly participants in... View Article

New member | ClinGroup

5 May 2024

ClinGroup is a full CRO of 6 Business Units providing Comprehensive Solutions For Health industry R&D; Established since 2002& Expanding... View Article

New member | My-Serious-Game

5 May 2024

Founded in 2014, My-Serious-Game is the French leader in custom-built digital learning solutions and a key European player: from analyzing... View Article

OSE Immunotherapeutics Receives U.S. Patent Notice of Allowance for Tedopi®

5 May 2024

Further Strengthens Global Intellectual Property Portfolio for Tedopi® in Non-Small Cell Lung Cancer until 2035 OSE Immunotherapeutics announced today that... View Article

Valneva: U.S. DoD Exercises First Year Option on IXIARO® Supply Contract

5 May 2024

Valneva, a specialty vaccine company, today announced that the U.S. Department of Defense (DoD) has exercised the first option of... View Article